Rating Change
Needham analysts reiterated a Buy rating on Pacira BioSciences, Inc. (NASDAQ:PCRX) on August 05, 2026.
reiterateNASDAQ:PCRX
Needham Reiterates Buy Rating on Pacira BioSciences, Inc. (PCRX)
Rating Change Needham analysts reiterated a Buy rating on Pacira BioSciences, Inc. (NASDAQ:PCRX) on August 05, 2026. Market Context Pacira BioSciences, Inc.
Market Context
Pacira BioSciences, Inc. operates in the Healthcare sector. The stock currently trades at $25.01 with a market capitalization of $1.2B.
Analyst coverage from Needham provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Pacira BioSciences, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Pacira BioSciences, Inc.
Among the 10 most recent ratings: 7 Buy, 3 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 05, 2026 | Needham | Buy | N/A |
| Jul 01, 2026 | HC Wainwright & Co. | Buy | N/A |
| May 01, 2026 | RBC Capital | Sector Perform | N/A |
| May 01, 2026 | Needham | Buy | N/A |
| Mar 26, 2026 | Barclays | Equal-Weight | N/A |
Related Tools: Analyst Ratings Dashboard | View PCRX Stock Page
Frequently Asked Questions
What does a Buy rating mean for PCRX?
A Buy rating from Needham reflects the analyst's outlook on Pacira BioSciences, Inc. (NASDAQ:PCRX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the PCRX forecast page.